Objective: To analyze the clinical date of 4 patients who developed very late stent thrombosis after implantation of sirolimus eluting stents.
Methods: From Oct. 2002 to Aug. 2006, 835 sirolimus eluting stents were implanted in 612 patients. From Jan. 2006 to Aug. 2006, very late thrombosis in sirolimus eluting stents occurred in 4 patients (0.65%), and which caused acute myocardial infarction in anterior wall. Emergency percutaneous coronary interventions (PCIs) were performed in 4 patients immediately after re-admission. The clinical date of the 4 cases were analyzed retrospectively.
Results: These 4 patients were male with the age of 40-69 years. Very late stent thrombosis occurred 31-37 months after successful implantation of sirolimus eluting stents. Application of clopidogrel was stopped 7-12 months after first stents implantation. Aspirin was continued in 3 patients, while the other patient discontinued taking aspirin 18 moths before thrombosis occurred. Emergency coronary angiogram showed that sirolimus eluting stents in LADs were all occlude by thrombosis with TIMI 0 flow. All 4 patients survived after successfully primary PCIs.
Conclusions: Our report presents evidence of very late thrombosis in sirolimus eluting coronary stents, and more careful and prolonged flow-up was required in patients after implantation of drug eluting stents.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Long-Term Outcomes of True versus Non-True Coronary Bifurcation Lesions Treated with Bioresorbable Polymer Sirolimus-Eluting Ultimaster Stent under Intravascular Imaging Guidance.
Am J Cardiol
December 2024
Department of Cardiovascular Medicine, Sapporo Cardiovascular Clinic, Sapporo Heart Center, Sapporo, Japan.
Limited evidence exists regarding the long-term outcomes of true vs. non-true coronary bifurcation lesions (CBLs) treated with current-generation drug-eluting stents and intravascular imaging guidance. The SCVC (Sapporo Cardiovascular Clinic) registry was a prospective, single-center, all-comers registry enrolling 1,727 consecutive patients treated with bioresorbable polymer sirolimus-eluting stent (BP-SES) under complete imaging guidance.
View Article and Find Full Text PDFSafety and Efficacy of BioMime Sirolimus-Eluting Stent System in All-Comers Real-World Population With Coronary Artery Stenosis: MILES Global Registry.
Cardiol Res
December 2024
Department of Forensic Medicine, Imam Khomeini Hospital, Tehran, Iran.
Background: This study evaluated the safety and efficacy of BioMime sirolimus-eluting stent (SES) system, with an ultra-low strut thickness (65 µm), in real-world all-comers population with coronary artery stenosis (CAD).
Methods: This was a post-marketing, multicenter, single-arm, observational clinical registry among patients undergoing intervention for CAD. Patients were clinically followed up at 1, 9, 12, and 24 months after the index percutaneous coronary intervention.
Safety and Efficacy of Two Ultrathin Biodegradable Polymer Sirolimus-Eluting Stents in Real-World Practice: Genoss DES Stents Versus Orsiro Stents From a Prospective Registry.
Clin Cardiol
December 2024
Division of Cardiology, Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, South Korea.
Background: The Orsiro and Genoss DES stents are biodegradable polymer drug-eluting stents (DESs) with ultrathin struts.
Objective: To investigate the safety and efficacy of these two ultrathin DESs in real-world practice.
Methods: From a single-center prospective registry, we included 751 and 931 patients treated with the Genoss DES and Orsiro stents, respectively.
Long-term efficacy of drug-coated balloon only angioplasty for IgG4-related coronary artery disease: a case report.
Eur Heart J Case Rep
October 2024
Department of Cardiology, Matsunami General Hospital, Kasamatsu, Gifu 501-6062, Japan.
Background: Although coronary artery involvement in patients with IgG4-related disease (IgG4-RD) is rare, emergency revascularization is recommended for managing acute coronary syndrome. However, coronary aneurysm formation and stent migration after sirolimus-eluting stent implantation have been reported for this disease. Thus, new treatment modalities are warranted for the management of coronary artery disease in this vasculitis.
View Article and Find Full Text PDFDrug-Coated Balloons in Percutaneous Coronary Intervention: Beyond Evidence.
Cureus
November 2024
Cardiology, Lebanese American University School of Medicine, Beirut, LBN.
Drug-coated balloons (DCBs) represent a promising alternative to drug-eluting stents (DESs) by adopting a "leave-nothing-behind" approach, avoiding the long-term implantation of metallic materials associated with vessel damage, stent thrombosis, and restenosis. Although DCBs have historically been indicated for patients with in-stent restenosis or de novo small-vessel disease, recent studies indicate the potential for broader applications in acute coronary syndromes (ACSs). Trials comparing DCB and DES treatments show that DCBs yield comparable long-term outcomes, with some studies suggesting reduced rates of secondary endpoints such as cardiac death and non-fatal myocardial infarction among ACS patients treated with DCBs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!